TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12820279

Group type: EXPERIMENTAL
Intervention: Joint piecewise exponential joint model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard proportional hazards model
Number of subjects: 0
Study: 11303962

Group type: EXPERIMENTAL
Intervention: Glycyrrhetic acid (GA) ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human PBPK model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated licorice consumption
Number of subjects: 0
Study: 8784096

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (2 IU/m2 day)
Number of subjects: 29
Study: 1732485

Group type: EXPERIMENTAL
Intervention: Single-dose oral administration of a combination of rapid- and slow-release diclofenac (Voltaren)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of intramuscular diclofenac and an oral depot formula
Number of subjects: 0
Study: 6370978

Group type: EXPERIMENTAL
Intervention: Nomifensine (100-150 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Imipramine (100-150 mg/day)
Number of subjects: 36
Study: 29265423

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 28513784

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution with alcohol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution without alcohol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 25599737

Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg intravenous infusion within 2 days after transplantation and 3 months later)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no pamidronate, received calcium and vitamin D supplementation)
Number of subjects: 40
Study: 23163418

Group type: EXPERIMENTAL
Intervention: Cabergoline (1.25 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 25
Study: 21867502

Group type: COMPARATOR
Intervention: Standard facilitated online group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prosocial facilitated online group (includes structured helping opportunities and coaching)
Number of subjects: 0
Study: 19145720

Group type: EXPERIMENTAL
Intervention: Oral health promotion programme for parents (test group)
Number of subjects: 649

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 649
Study: 16257151

Group type: EXPERIMENTAL
Intervention: Isoflavone (300 mg standardized soy extract with 120 mg isoflavones/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Estrogen (0.625 mg conjugated equine estrogens + placebo)
Number of subjects: 79
Study: 12948999

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 201
Study: 11338491

Group type: EXPERIMENTAL
Intervention: Open flap débridement with bioactive glass particles
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open flap débridement (control)
Number of subjects: 12
Study: 8865524

Group type: EXPERIMENTAL
Intervention: 250 mg bid ticlopidine for 4 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1509996

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 16
Study: 6090020

Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 29

Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 29

Group type: COMPARATOR
Intervention: antacid
Number of subjects: 29
Study: 30670280

Group type: EXPERIMENTAL
Intervention: Rhythmical massage once a week for three months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback 15 min daily for three months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 27800653

Group type: EXPERIMENTAL
Intervention: Virtual Patients (VP)
Number of subjects: 34
Study: 26644038

Group type: EXPERIMENTAL
Intervention: Part Task (PT) training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Whole Task (WT) training
Number of subjects: 44
Study: 24316699

Group type: EXPERIMENTAL
Intervention: Oraqix®
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hurricaine®
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vaseline
Number of subjects: 15

Group type: COMPARATOR
Intervention: No anesthetic
Number of subjects: 15
Study: 23016531

Group type: EXPERIMENTAL
Intervention: Q-Switched Nd:YAG laser (1064 nm) at 5 J/cm2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Q-Switched Nd:YAG laser (1064 nm) at 15 J/cm2
Number of subjects: 16
Study: 19142552

Group type: EXPERIMENTAL
Intervention: Target glucose level of 80-130 mg/dl
Number of subjects: 109

Group type: COMPARATOR
Intervention: Target glucose level of 160-200 mg/dl
Number of subjects: 109
Study: 17292730

Group type: EXPERIMENTAL
Intervention: 30 g of almonds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 60 g of almonds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 90 g of almonds
Number of subjects: 9

Group type: COMPARATOR
Intervention: White bread alone (control)
Number of subjects: 9
Study: 15592001

Group type: EXPERIMENTAL
Intervention: Mandibular overdentures retained by a magnet attachment (mainly mucosa-supported overdenture)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mandibular overdentures retained by a bar attachment (combined mucosa-implant-supported overdenture)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Magnet-retained overdentures
Number of subjects: 10

Group type: COMPARATOR
Intervention: Combined mucosa-implant-supported overdentures
Number of subjects: 10
Study: 11305706

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 2700
Study: 9538375

Group type: EXPERIMENTAL
Intervention: Bepridil (300 mg/day in 3 doses)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Diltiazem (180 mg/day in 3 doses)
Number of subjects: 148
Study: 8370371

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg o.d. for 3 weeks, increased to 100 mg o.d. for final 3 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg b.d. for 3 weeks, increased to 20 mg b.d. for final 3 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nicorandil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 37
Study: 3092601

Group type: EXPERIMENTAL
Intervention: Metamizol (2.5 g)
Number of subjects: 4

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Continual chemical stimulation with metamizol
Number of subjects: 4
Study: 31881877

Group type: EXPERIMENTAL
Intervention: Comprehensive community intervention (patient intervention and community climate interventions)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Control group (no comprehensive intervention)
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Comprehensive community intervention
Number of subjects: 1538
Study: 27743215

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (SEA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Total-etch adhesive (TEA)
Number of subjects: 41
Study: 26091568

Group type: EXPERIMENTAL
Intervention: Grandio resin composite restorations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tetric Ceram resin composite restorations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Overall wear and marginal quality
Number of subjects: 30
Study: 24982069

Group type: EXPERIMENTAL
Intervention: TOL-TAZ plus metronidazole (1.5 g TOL-TAZ every 8 hours with 500 mg metronidazole every 8 hours)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Meropenem (1 g every 8 hours)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: TOL-TAZ
Number of subjects: 121

Group type: COMPARATOR
Intervention: TOL-TAZ and meropenem (both groups)
Number of subjects: 121
Study: 22561357

Group type: EXPERIMENTAL
Intervention: 250 mg of oral caffeine
Number of subjects: 14
Study: 19886384

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (150 mg) intramuscularly every 2 weeks for 12 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study: 18090078

Group type: EXPERIMENTAL
Intervention: Circumferential fusion
Number of subjects: 146

Group type: COMPARATOR
Intervention: Posterolateral fusion
Number of subjects: 146
Study: 15064097

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg/day, 6 week treatment)
Number of subjects: 25
Study: 12198659

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Endoscopic ligation
Number of subjects: 49
Study: 10051462

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy (13-15 mg/kg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (D-penicillamine or placebo)
Number of subjects: 16
Study: 7674408

Group type: EXPERIMENTAL
Intervention: Unreamed interlocking nail
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hoffmann external skeletal fixation (ESF)
Number of subjects: 36
Study: 2254100

Group type: EXPERIMENTAL
Intervention: Postmastectomy irradiation + CMF (protocol 82-b)
Number of subjects: 2675

Group type: COMPARATOR
Intervention: CMF alone (protocol 82-b)
Number of subjects: 2675

Group type: EXPERIMENTAL
Intervention: Postmastectomy irradiation + Tamoxifen (protocol 82-c)
Number of subjects: 2675

Group type: COMPARATOR
Intervention: Tamoxifen alone (protocol 82-c)
Number of subjects: 2675
Study: 7456097

Group type: EXPERIMENTAL
Intervention: Radiotherapy (60Co-irradiation)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 15
Study: 31702058

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment in groups (MBT-G)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 112
Study: 31021041

Group type: EXPERIMENTAL
Intervention: Chemical peeling (trichloroacetic acid and lactic acid), four sessions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) injection, four sessions with 2 weeks intervals
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Side effects reported for chemical peeling
Number of subjects: 42

Group type: COMPARATOR
Intervention: Side effects reported for PRP
Number of subjects: 42
Study: 28131654

Group type: EXPERIMENTAL
Intervention: Febuxostat (ULORIC® tablet, 80 mg)
Number of subjects: 42
Study: 25592412

Group type: EXPERIMENTAL
Intervention: Selegiline (10mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard rehabilitation care (both groups)
Number of subjects: 47
Study: 23726433

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition + Ecoimmunonutrition (EN + EIN)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 183
Study: 21366911

Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 19126411

Group type: EXPERIMENTAL
Intervention: Pursuit of a Gaussian blob in a step‐ramp paradigm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pursuit analysis intervals of 400‐500ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speed discrimination thresholds determined for different presentation durations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor system contribution to smooth pursuit eye movements
Number of subjects: 0
Study: 17261682

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (stimulator off)
Number of subjects: 7
Study: 12632617

Group type: EXPERIMENTAL
Intervention: Moderate-dose group (M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose group (H)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 10
Study: 10942743

Group type: EXPERIMENTAL
Intervention: Biatrial pacing (BiA)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Left atrial pacing (LA)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Right atrial pacing (RA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No pacing (control)
Number of subjects: 132
Study: 8979783

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 20
Study: 1609525

Group type: EXPERIMENTAL
Intervention: Preventive massage ointment administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 24
Study: 6743779

Group type: EXPERIMENTAL
Intervention: Nifedipine capsule (Adalat, Bayer) 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nifedipine tablets (Taro) 10 mg
Number of subjects: 8
Study: 2940971

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (various doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg every 12 h
Number of subjects: 28
Study: 31421011

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% for 12 months (Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Timolol 0.5% for 3 months (Group B)
Number of subjects: 86
Study: 29141241

Group type: EXPERIMENTAL
Intervention: TIMP-1 levels at day 3
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: EMMPRIN, MMP-9, and TIMP-1 levels
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: MMP-9
Number of subjects: 243
Study: 26950240

Group type: EXPERIMENTAL
Intervention: Support‐Transform‐Achieve‐Results (STAR) workplace intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual-practice group (control)
Number of subjects: 103
Study: 24646100

Group type: EXPERIMENTAL
Intervention: KTP laser therapy (0.8W, time on 50 ms, time off 50 ms, 30 s, 532 nm) followed by SRP
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 24
Study: 22396084

Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous tramadol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous tramadol + 330 mg paracetamol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 20869570

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo matching sprays
Number of subjects: 70
Study: 18622275

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15671125

Group type: EXPERIMENTAL
Intervention: Propranolol (25 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12864826

Group type: EXPERIMENTAL
Intervention: Well-designed randomized controlled trials of surgical procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive approach to surgical outcomes assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternate study designs
Number of subjects: 0
Study: 11000077

Group type: EXPERIMENTAL
Intervention: Chitosan dressing
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 2
Study: 8813039

Group type: EXPERIMENTAL
Intervention: Zidovudine alone
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Didanosine alone
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Higher baseline concentrations of plasma HIV RNA
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Less suppression of plasma HIV RNA by treatment
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Presence of syncytium-inducing phenotype
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: CD4 cell counts
Number of subjects: 391
Study: 1603387

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg, twice daily for 5 days)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg, twice daily for 5 days)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 142

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Norfloxacin and TMP/SMX
Number of subjects: 142
Study: 6399927

Group type: EXPERIMENTAL
Intervention: Oral leucine at a dose of 0.2 g per kg per day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral leucine
Number of subjects: 96
Study: 30428063

Group type: EXPERIMENTAL
Intervention: Paclitaxel with trametinib
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Paclitaxel with pazopanib
Number of subjects: 111

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 111
Study: 30188798

Group type: EXPERIMENTAL
Intervention: Transdermal T gel targeting lower [400‐550 ng/dL] T range
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Transdermal T gel targeting higher [600‐1000 ng/dL] T range
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No exercise (control for PRT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 160
Study: 27319812

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% NaCl solution (control group)
Number of subjects: 20
Study: 24983989

Group type: EXPERIMENTAL
Intervention: Live oral cholera vaccine VA 1.4 (1.9×10^9 CFU)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 22441135

Group type: EXPERIMENTAL
Intervention: Statin therapy for 8 months in group D (DM (‐), HT (‐))
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Statin therapy in group A (DM (+), HT (+))
Number of subjects: 119

Group type: COMPARATOR
Intervention: Comparison of mean percent change of atheroma volume between groups A and D
Number of subjects: 119

Group type: COMPARATOR
Intervention: Statin therapy in all groups
Number of subjects: 119
Study: 19931157

Group type: EXPERIMENTAL
Intervention: Playing SimCity for six weeks
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 248
Study: 18243335

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All antipsychotic treatments
Number of subjects: 56
Study: 16012274

Group type: EXPERIMENTAL
Intervention: Nocturnal intravenous TRH 500 microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 12887812

Group type: EXPERIMENTAL
Intervention: Lactulose (15 - 90 ml/day) for 8 weeks in Stg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lactulose (15 - 90 ml/day) for 24 weeks in Ltg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (Cg) with no lactulose treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (Cg)
Number of subjects: 64
Study: 11232539

Group type: EXPERIMENTAL
Intervention: More elaborate encoding task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8653868

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted terminal blood cardioplegia (LDTC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Terminal blood cardioplegia (TC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Whole blood (WB)
Number of subjects: 30
Study: 1455377

Group type: EXPERIMENTAL
Intervention: Chondroprotective therapy; specific drugs not mentioned; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chondroprotective drugs; specific drugs not mentioned; details on dosage and duration not available.
Number of subjects: 0
Study: 3877900

Group type: EXPERIMENTAL
Intervention: High and low frequency transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mechanical vibratory stimulation at 100 Hz
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 50
Study: 31470759

Group type: EXPERIMENTAL
Intervention: ADRC
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 29564661

Group type: EXPERIMENTAL
Intervention: Sonographic evaluation by medical students after training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gold standard evaluation by an experienced consultant
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Repetitions of the sonographic task
Number of subjects: 10
Study: 26433782

Group type: EXPERIMENTAL
Intervention: 250 mg of cadazolid twice daily for 10 days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 500 mg of cadazolid twice daily for 10 days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 1000 mg of cadazolid twice daily for 10 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: 125 mg of vancomycin four times daily for 10 days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All cadazolid doses
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All C. difficile isolates
Number of subjects: 84
Study: 24178631

Group type: EXPERIMENTAL
Intervention: Face-to-face interview (FFI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone interview (TI)
Number of subjects: 0
Study: 22930737

Group type: EXPERIMENTAL
Intervention: Time-varying magnetic fields (TVMF) within a static magnetic stray field (SMF) of a 7 Tesla MRI scanner
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham (0 T) exposure
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low (0.5 T) SMF exposure
Number of subjects: 31

Group type: COMPARATOR
Intervention: High (1.0 T) SMF exposure
Number of subjects: 31